Tennis Serves Up Economic Wins for France at Roland-Garros
At a time of weak economic growth and consumer spending in France, the business of sport is proving to be a much-needed lifeline
Bonjour et Bienvenue to the Paris Edition. I'm Bloomberg Opinion columnist Lionel Laurent. If you haven't yet, subscribe now to the Paris Edition newsletter.
One of France's top sporting rendezvous is underway: The Roland-Garros tennis tournament, or the French Open, where lobs, smashes and aces are served up on a clay court under the bobbing heads of fans, VIPs and lucky corporate guests in swish lodges.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Car and Driver
an hour ago
- Car and Driver
Report: Most 2026 BMW Models Will Receive a Price Hike on July 1
BMW will raise prices on many of its 2026 models starting on July 1, according to a report from CarsDirect. The increase will amount to about 2 percent of the existing MSRP, with the price hike ranging from $1100 to $2500. Several models will escape the price bump, including the 2026 iX SUV and 2026 M2 coupe. The vast majority of BMW models will likely get more expensive starting next month. As reported by CarsDirect, a bulletin was sent to BMW dealerships last week stating that the MSRP of most 2026 BMW models will go up by 1.9 percent beginning on July 1, 2025. The price increases will reportedly not affect 2025 BMW inventory. BMW has so far released pricing for many, but not all, of its 2026 model year lineup, with pricing for models such as the 7-series, X1, and 2-series not yet available. The nearly 2 percent price increase also won't affect every model in BMW's lineup. The main exceptions are its 2026-model-year EVs, the i5 and the iX. (Pricing for the 2026 i4 and i7 has not been published.) The Alpina XB7, 2026 2-series Gran Coupe, and 2026 M2 are also reportedly unaffected. BMW On the top end, the price hikes amount to $2500 for models such as the X5 M, which rises from $127,200 to $129,700, according to CarsDirect. The lowest increases are for the 4-series Coupe and Z4 roadster, which each see a bump of $1100. These figures exclude the destination fee, which Car and Driver reports as part of the price, and it's unclear if the freight charge will change for any BMW models when the calendar turns to July. CarsDirect says the bulletin doesn't blame the import tariffs implemented by the U.S. government for the price hikes, instead stating that the rises are "in line with past pricing communications, and account for inflation and enhancements to standard equipment where applicable." Slight increases in the MSRP are common for new model years, but we wouldn't be surprised if the tariffs are also playing a factor. A previous report from Automotive News stated that BMW wouldn't raise prices on imported models until the end of June. We've reached out to BMW for comment regarding these reported price increases and will update the story if we hear back. Caleb Miller Associate News Editor Caleb Miller began blogging about cars at 13 years old, and he realized his dream of writing for a car magazine after graduating from Carnegie Mellon University and joining the Car and Driver team. He loves quirky and obscure autos, aiming to one day own something bizarre like a Nissan S-Cargo, and is an avid motorsports fan.
Associated Press
an hour ago
- Associated Press
Sire Search Identifies Top 5 Platforms to Boost Biotech Career Growth
Hey, biotech folks! Whether you're a lab whiz itching to land your next role in drug discovery or a hiring manager hunting for the perfect candidate to boost your startup, the life sciences world is buzzing with potential. But, real talk—finding the right job or talent in this fast-moving industry can feel like trying to spot a single cell under a microscope. Overwhelming, right? That's were specialized recruitment websites swoop in like career superheroes. I've rounded up the five best platforms to help you navigate the biotech job maze, and guess what? SIRE Searchis leading the charge with its sharp, tailored approach. Let's dive in and see why these sites are your new allies for crushing it in biotech! 1. – Your Career's Guide A recruitment platform that feels like it knows you better than your lab partner. That's SIRE Searchin a nutshell. Based in Haarlem, Netherlands—a charming spot, by the way—SIRE has been shaking up the life sciences scene since 2012. Whether you're into pharmaceuticals, medical devices, or even fast-moving consumer goods (yep, they've got that covered), SIRE's the place to find your next career win. Their reverse recruitment approach is like a secret weapon. Instead of tossing a pile of job listings your way, they do the heavy lifting first. Using data and market insights, their team—packed with recruiters who actually get biotech—handpicks roles that match your skills and goals. One Trustpilot reviewer raved, 'SIRE landed me a job that's spot-on for my expertise. They were quick and genuinely cared!' With a 4-star rating, they're clearly hitting the mark. 2. – The U.S. Biotech Hub Let's zip over to the States for BioSpace, a heavyweight for biotech and pharma jobs. With over 4,000 active listings, this sites like a treasure chest for anyone looking to dive into or climb higher in the U.S. biotech scene. From lab techs to execs, BioSpace has roles for every step of your journey. What's the deal with BioSpace? It's more than a job board—it's a whole community. You can narrow down searches by niche (like gene therapy or clinical trials) or location, so you're not stuck scrolling through irrelevant posts. They also dish out extras like industry updates, career tips, and their 'Best Places to Work' report, which is like a VIP list for biotech companies. The downside? It's mostly U.S.-focused, so it doesn't have SIRE's global reach. But for North American job seekers, BioSpace is a goldmine. 3. – Your Global Career Connector Dreaming of a biotech career that takes you worldwide? Meet Preclinical. With offices in places like the UK, Singapore, and the U.S., this platform hooks up candidates with roles in everything from drug development to regulatory affairs. It's like having a friend who knows the hottest jobs on every continent. Proclinical's strength is precision. Their recruiters dig into what employers need—skills, culture, the whole package—and match that with a huge candidate network. It's like they're playing career matchmaker, and they're good at it. They don't have SIRE's data-driven reverse recruitment trick, but their global scope is a big win for anyone wanting to think beyond borders. Plus, their blog's full of practical tips, like how to tweak your CV or nail an interview, which is super handy. 4. – The Science Lover's Hangout Next up is New Scientist Jobs, the friendly, all-purpose spot for science buffs. It covers a range of fields, but its biotech section is packed with roles in areas like vaccine research or molecular biology. Whether you're in Europe, the U.S., or elsewhere, this platform's global vibe makes it a welcoming place to explore. Why's it worth your time? It's easy to navigate, with filters to zero in on jobs by expertise or location. Their blog's a gem, too, with career advice and industry scoops that keep you in the loop. It's not as biotech-focused as SIRE, so you might need to sift a bit to find the right role. But if you're curious and love poking around, New Scientist Jobs is a solid bet. 5. – The Job-Finding Shortcut Last up is BioPharmGuy, the quirky underdog we're rooting for. Instead of hosting job listings, it points you straight to biotech company career pages, helping you dodge crowded job boards and find hidden opportunities. It's like a map of buried treasure. You can search by region or niche—like cell therapy or diagnostics—which makes it easy to target your sweet spot. The catch? It's more of a DIY experience, so you won't get the hands-on support you'd find with SIRE's recruiters. But for those who enjoy a bit of career sleuthing, BioPharmGuy is a clever tool to stand out. Why SIRE Search Takes the Crown? Let's give a shoutout to SIRE Searchfor stealing the show. Their reverse recruitment strategy is like having a career coach who's always one step ahead. By tapping into data and market trends, they find roles that fit you like a perfectly calibrated pipette. Their recruiters are biotech enthusiasts who speak your language and genuinely care about your next step. SIRE's focus on Europe—where biotech is thriving—gives them the edge, with connections to everyone from tiny startups to massive corporations. One candidate on Trustpilot said, 'SIRE made my job search feel effortless. They found me a role that's exactly where I want to be.' Employers love them, too, thanks to their knack for delivering candidates who nail both the skills and the vibe. Whether you're after a temp role or a corner office, SIRE's your partner in crime. 5 Tips to Nail Your Biotech Job Hunt Ready to hit these websites and land your dream role? Here's how to make it happen: Let's Wrap It Up The biotech world is full of possibilities, and these websites are your key to unlocking them. SIRE Searchleads the pack with its smart, personalized approach and deep love for life sciences. BioSpace, Preclinical, New Scientist Jobs, and BioPharmGuy are also stellar, each bringing their spark to the table. So, spruce up that resume, dive into these platforms, and get ready to make waves in biotech. Your next big opportunity is out there—grab it! Media Contact Company Name: Sire Search Email: Send Email Address:Staten Bolwerk City: 12011 MK Haarlem Country: Netherlands Website: Press Release Distributed by To view the original version on ABNewswire visit: Sire Search Identifies Top 5 Platforms to Boost Biotech Career Growth
Associated Press
an hour ago
- Associated Press
CCV Group Invests in Rezonate to Redefine the Future of Music Royalties for Producers and Creators
United Kingdom, June 6, 2025 -- CCV Group ( ), a venture capital firm focused on the intersection of culture, media, and technology, is proud to announce a strategic investment in Rezonate, a pioneering rights platform reshaping how music producers and back-end creators monetize their work. Founded by acclaimed producer Cam Blackwood and former investment banker Tom Tyler, Rezonate is building a new asset class by acquiring and managing royalty streams from music producers, engineers, and other behind-the-scenes talent. The company leverages cutting-edge data and rights tracking to ensure transparency, equity, and long-term value in an industry that has historically undervalued these contributors. Rezonate is also backed by Bridgepoint, one of Europe's most experienced credit managers, which in June announced the provision of up to $150 million worth of capital to accelerate the platform's growth and fuel a pipeline of high-profile producer catalogue acquisitions. Today's investment will accelerate Rezonate's growth across Europe and the U.S., scale its acquisition pipeline, and further build out its proprietary platform for rights management. John Darling, CEO of CCV Group, said: 'We believe the next wave of cultural value will be built on infrastructure that respects and empowers creators. Rezonate is unlocking a hidden layer of music IP—bringing transparency, liquidity, and dignity to the producers and engineers who shape the sound of generations. This is exactly the kind of cultural infrastructure we're here to back.' Cam Blackwood, Producer and Co-founder of Rezonate, said: 'For years, producers and engineers have shaped iconic records without sharing in their long-term value. Rezonate is about fixing that—giving creative professionals the financial tools and recognition they've always deserved. We're thrilled to have CCV's support as we scale this mission globally.' Tom Tyler, Co-founder of Rezonate, said: 'We're building an institutionally credible, data-led platform that can manage and grow the royalty income of the music industry's unsung heroes. With CCV's investment, we're not just gaining capital we're gaining a partner that understands the long-term thesis around creator-led IP.' This partnership signals a broader shift in the music rights landscape. While most funds focus on front-facing artist catalogs, Rezonate is leading a new movement focused on backend creators those who've traditionally had fewer paths to liquidity or legacy building. About CCV Group CCV Group is a venture capital firm investing in early and growth-stage companies at the intersection of culture, technology, and media. With a team of experienced founders and operators, CCV partners with bold entrepreneurs to build enduring companies that shape the cultural economy. About Rezonate Rezonate is a rights management and royalty acquisition company focused on music producers, engineers, and creators behind the scenes. By combining rights aggregation, financial structuring, and advanced metadata tracking, Rezonate empowers creators to unlock and protect the long-term value of their work. About Bridgepoint Bridgepoint Group is one of the world's leading quoted private asset growth investors, specialising in private equity, infrastructure and private credit. With over $75 billion of assets under management and a strong local presence in Europe, North America and Asia, they combine global scale with local market insight and sector expertise, consistently delivering strong returns through cycles. Contact Info: Name: John Darling Email: Send Email Organization: Creative Capital Ventures Website: Release ID: 89161804 If there are any errors, inconsistencies, or queries arising from the content contained within this press release that require attention or if you need assistance with a press release takedown, we kindly request that you inform us immediately by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our reliable team will be available to promptly respond within 8 hours, taking proactive measures to rectify any identified issues or providing guidance on the removal process. Ensuring accurate and dependable information is our top priority.
